blindness and tirzepatide Does Cause Nightmares? Side Effects Explained Researchers Find Small Increased Risk

This is among the three main factors that have motivated public (health professionals) and patients (consumers) to increasingly seek liposomal formulations

Real world evidence will be critical in determining durability of effect, adherence, and tolerability across diverse patient populations

About a dozen states addressed the coverage of GLP-1 drugs during 2024 sessions, but the patchwork of policy pursuits largely failed

(Photo by Shalina Chatlani/Stateline) Massachusetts and Rhode Island are considering dropping GLP-1 drugs for obesity treatment from their Medicaid programs, continuing a trend of states that have stopped coverage of these expensive medications